First AD

Second AD

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Management of Emetogenicity of Antibody-Drug Conjugates

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Updates on HER2-Directed ADCs Across Solid Tumors

Peer Exchange

University of Illinois Cancer Center

Cancer Centers

Partner

Dana-Farber Cancer Institute

The Tisch Cancer Institute at Mount Sinai 

UCLA Health Jonsson Comprehensive Cancer Center

Assessing HER2 Status Across Tumor Types

ADCs Targeting HER2+ Breast Cancer

ADCs Targeting HER2+ Gynecologic Cancers

Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

ADCs Targeting GI Cancers

ADCs Targeting HER2+ Lung Cancer

Impact of ADCs on Brain Metastases

ADCs Targeting HER2+ GU Cancers

Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

Managing ILD and Pneumonitis Risk From ADCs

Managing Toxicities in Short- and Long-Term Treatment with ADCs

Managing Hematologic AEs Associated with ADC Treatments

ADC Sequencing

Emerging ADCs in Development

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

The Future for HER2-Directed ADCs

Key Takeaways and Closing Thoughts on ADCs